TTK Healthcare to Sell Eva and Good Home Brands to Wipro for ₹256 Crore

Market snapshot: TTK Healthcare Limited has approved the divestiture of its popular personal care brand Eva and home care brand Good Home to Wipro Enterprises Private Limited for ₹256 crore plus GST. The definitive agreements were executed on July 23, 2026, with the transaction slated to close by September 30, 2026.

Data Snapshot

• Wipro Enterprises will acquire the Eva and Good Home brands for ₹256 crore plus GST.
• The divested brands recorded a combined revenue of approximately ₹148 crore in FY 2025-26.
• The brands accounted for approximately 17% of TTK Healthcare's total turnover of ₹857.28 crore in the last fiscal year.

What's Changed

• TTK Healthcare's overall revenue from operations grew around 7% YoY to ₹857.28 crore in FY26, up from ₹801.49 crore in FY25.
• However, the company's full-year Net Profit declined 19.57% to ₹65.68 crore in FY26 compared to ₹81.66 crore in FY25 due to segment headwinds in protective devices.
• The divestment of the Eva and Good Home brands represents a significant restructuring of the consumer division, liquidating non-core assets to lock in ₹256 crore of liquidity.

Key Takeaways

• Strategic Brand Divestment: TTK Healthcare is selling its cosmetics brand Eva and home cleaning range Good Home, enabling a streamlined corporate structure.
• Cash Infusion: The transaction brings in ₹256 crore (plus GST) in cash, significantly boosting the company's already comfortable cash reserves of ₹927 crore reported as of June 2025.
• Attractive Valuation: At ₹256 crore, the sale is valued at approximately 1.73x the brands' FY26 revenue of ₹148 crore.
• Wipro Enterprises Expansion: The acquisition allows Wipro Enterprises to expand its consumer product portfolio in the personal care and home care segments.

SAHI Perspective

The brand sale is highly value-accretive for TTK Healthcare. Divesting the personal and home care brands for ₹256 crore (≈1.73x FY26 brand sales of ₹148 crore) allows the company to realize substantial cash from segments where it faced intense competitive pressure and low margins. Crucially, as of mid-2025, the company was sitting on ₹927 crore in unencumbered cash from its previous Human Pharma division sale. This transaction further swells the treasury, presenting the management with a massive capital allocation decision: whether to reinvest in high-margin segments like Medical Devices or reward shareholders with substantial payouts.

Market Implications

For TTK Healthcare, the cash inflow strengthens its balance sheet and negative net-debt position. The market is likely to view this restructuring positively, as the company exits lower-margin, high-marketing-spend consumer segments (like cosmetics, which required substantial brand ambassador outlays). For Wipro Enterprises, this marks a strategic consolidation of its FMCG presence, leveraging its extensive distribution reach to scale Eva and Good Home.

Trading Signals

Market Bias: Bullish

The divestment of Eva and Good Home brands for ₹256 crore plus GST will significantly boost TTK Healthcare's cash reserves. At an attractive valuation of ~1.73x FY26 revenue of ₹148 crore, the transaction is expected to unlock value, streamline operations, and support the stock's performance.

Overweight: FMCG, Healthcare

Trigger Factors:

• Successful completion of the deal by September 30, 2026.
• Management commentary on the utilization of the ₹256 crore proceeds.
• Execution of brand transition and operational performance of remaining segments like Medical Devices.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian FMCG and personal care space is witnessing intense competition and consolidation. Smaller players are finding it capital-intensive to scale personal care brands like Eva due to rising marketing costs and the need for celebrity endorsements. Divestments to larger conglomerates like Wipro Enterprises, which have the distribution muscle and capital to nurture such brands, have become a common industry theme.

Key Risks to Watch

• Revenue Loss: The divestment will lead to a 17% reduction in TTK Healthcare's topline (approx ₹148 crore) starting next fiscal year.
• Reinvestment Risk: With cash reserves set to exceed ₹1,100 crore post-deal, failure to deploy this capital into high-margin segments could drag down return metrics (ROE/ROCE).
• Transition Hurdles: Any delays in completing the customary closing conditions by the target date of September 30, 2026.

Recent Developments

TTK Healthcare recommended a dividend of ₹10 per share for FY26 on May 30, 2026, with the record date set as July 17, 2026. The company's 68th AGM is scheduled for July 24, 2026. Additionally, the trading window remains closed from July 1, 2026, until 48 hours post-Q1 FY27 earnings. The company also clarified on June 17, 2026, that it has not acquired any ₹250 crore stake in any pharma firm.

Closing Insight

This transaction is a textbook example of corporate restructuring where a mid-sized company exits highly competitive, marketing-heavy consumer niches to unlock massive liquid value. TTK Healthcare is now exceptionally liquid, and the upcoming AGM on July 24, 2026, will be closely watched for any hints on how this capital will be deployed.

High Performance Trading with SAHI.